Communiqués Moderna, Inc.

Actions

MRNA

US60770K1079

Produits pharmaceutiques

Temps réel estimé Cboe BZX 16:12:12 03/09/2026			Varia. 5j.	Varia. 1 janv.
146,64 ^USD	-2,77%		+2,05%	+394,05%

16:00	Moderna, Inc. : Evercore ISI maintient sa recommandation neutre	ZM
14:35	La fête est elle déjà finie pour les rois du momentum boosté à l'IA ?

Communiqués

01/09	Moderna to Present at Upcoming Conferences in September 2026	AQ
31/08	Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes	AQ
28/08	Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes	AQ
27/08	Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines	AQ
27/08	Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes	AQ
06/08	Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA	AQ
04/08	Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus	AQ
31/07	Moderna: Q2 Earnings Snapshot	AQ
31/07	Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
16/07	Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors	AQ
09/07	Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026	AQ
08/07	Moderna Appoints Michael McDonnell to Board of Directors	AQ
25/06	Moderna Science Day Highlights Expanding Potential of mRNA Platform	AQ
18/06	Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine	AQ
17/06	Moderna to Host Investor Event - Science Day	AQ
16/06	Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028	AQ
09/06	Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome	AQ
02/06	Moderna to Present at Upcoming Conference in June 2026	AQ
01/06	Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus	AQ
12/05	Moderna Recognized by TIME as One of the World's Most Impactful Companies	AQ
06/05	Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010	AQ
04/05	Moderna : Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
01/05	Moderna : Transcript (MRNA USQ Transcript 2026 05 01 1)	PU
01/05	Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
01/05	Moderna: Q1 Earnings Snapshot	AQ